Compare NTLA & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | ARCB |
|---|---|---|
| Founded | 2014 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2016 | N/A |
| Metric | NTLA | ARCB |
|---|---|---|
| Price | $13.82 | $86.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $17.32 | ★ $95.50 |
| AVG Volume (30 Days) | ★ 6.5M | 321.1K |
| Earning Date | 02-26-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.20 |
| Revenue | $57,528,000.00 | ★ $4,039,115,000.00 |
| Revenue This Year | $1.96 | N/A |
| Revenue Next Year | N/A | $3.52 |
| P/E Ratio | ★ N/A | $20.67 |
| Revenue Growth | ★ 33.52 | N/A |
| 52 Week Low | $5.90 | $55.19 |
| 52 Week High | $28.25 | $103.14 |
| Indicator | NTLA | ARCB |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 53.75 |
| Support Level | $13.86 | $85.88 |
| Resistance Level | $17.09 | $93.27 |
| Average True Range (ATR) | 1.28 | 2.95 |
| MACD | 0.29 | -0.69 |
| Stochastic Oscillator | 52.80 | 34.34 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.